Skip to main content

Drug Interactions between lanreotide and Lutathera

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

lanreotide lutetium Lu 177 dotatate

Applies to: lanreotide and Lutathera (lutetium lu 177 dotatate)

ADJUST DOSING INTERVAL: Somatostatin and its analogs may interfere with the therapeutic effects of lutetium Lu 177 dotatate by competitively binding to somatostatin receptors, the site of action for the radiolabeled agent. Lutetium Lu 177 dotatate is internalized upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumor cells, and subsequent beta emission from Lu 177 induces cellular damage by formation of free radicals in both target and neighboring cells.

MANAGEMENT: Long-acting formulations of somatostatin analogs should be discontinued for at least 4 weeks and short-acting formulations for at least 24 hours prior to each dose of lutetium Lu 177 dotatate. During treatment with lutetium Lu 177 dotatate, long-acting octreotide should be administered intramuscularly between 4 to 24 hours after each dose of lutetium Lu 177 dotatate (but not within 4 weeks of each subsequent dose of lutetium Lu 177 dotatate), while short-acting octreotide may be given as needed for symptomatic management (but not within 24 hours before each subsequent dose of lutetium Lu 177 dotatate). Following completion of lutetium Lu 177 dotatate treatment, long-acting octreotide should be continued every 4 weeks until disease progression or up to 18 months following treatment initiation.

References (1)
  1. (2022) "Product Information. Lutathera (lutetium Lu 177 dotatate)." Advanced Accelerator Applications

Drug and food interactions

Moderate

lanreotide food

Applies to: lanreotide

MONITOR: Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat. Clinical data are limited, however. In case reports, octreotide has been reported to reduce the relative bioavailability of cyclosporine. Transplant rejection and significant reductions in cyclosporine levels, sometimes to undetectable levels, have been reported in association with the interaction. Vitamin K absorption was not affected when concomitantly administered with lanreotide according to the manufacturer.

MANAGEMENT: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.

References (5)
  1. Landgraf R, Landgraf-Leurs MM, Nusser J, et al. (1987) "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation, 44, p. 724-5
  2. Ho PJ, Boyajy LD, Greenstein E, Barkan AL (1993) "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci, 38, p. 309-15
  3. Katz MD, Erstad BL (1989) "Octreotide, a new somatostatin analogue." Clin Pharm, 8, p. 255-73
  4. (2001) "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation
  5. (2007) "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer